Tourinho-Barbosa Rafael R, de la Rosette Jean, Sanchez-Salas Rafael
Department of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.
Department of Urology, Faculdade de Medicina do ABC (ABC Medical School), São Paulo, Brazil.
Curr Opin Urol. 2018 Nov;28(6):499-505. doi: 10.1097/MOU.0000000000000537.
Most of focal therapies has addressed index lesion as the targeted tumour focus to treat localized prostate cancer (PCa), a multifocal disease. The interaction between tumour foci and host cells creates a tumour microenvironment (TME) which affects tumour growth, cellular proliferation, and PCa progression. This review aims to better understand the biology of cancer foci and their interaction with the prostatic microenvironment after focal therapy.
Index lesions are representative of PCa grade in low-risk patients, but the other foci of tumour, the satellite lesions, gain relevance in higher risk patients. Multiparametric MRI, guided biopsies and new biomarkers in combination are important to address PCa multifocality and to adequately select patients to focal therapy. Stromal, immune, and tumoural components are integrated in tumourigenesis and modified after the inflammation induced by focal therapy.
TME and inflammation play an important role in PCa progression, but further researches are necessary to understand how once protective components of prostate microenvironment become protumour elements and how inflammation induced by focal therapy can affect them. Learning how to modulate TME is an exploratory molecular field that can lead us to better manage PCa in both prevention and treatment scenarios.
大多数局部治疗将索引病灶作为治疗局限性前列腺癌(PCa)的靶向肿瘤焦点,而PCa是一种多灶性疾病。肿瘤病灶与宿主细胞之间的相互作用形成了肿瘤微环境(TME),该微环境会影响肿瘤生长、细胞增殖和PCa进展。本综述旨在更好地了解局部治疗后癌灶的生物学特性及其与前列腺微环境的相互作用。
索引病灶代表低风险患者的PCa分级,但其他肿瘤病灶,即卫星病灶,在高风险患者中更为重要。多参数MRI、引导活检和新的生物标志物相结合,对于解决PCa的多灶性以及充分选择局部治疗的患者很重要。基质、免疫和肿瘤成分在肿瘤发生过程中相互整合,并在局部治疗引起的炎症后发生改变。
TME和炎症在PCa进展中起重要作用,但需要进一步研究以了解前列腺微环境中曾经的保护成分如何变成促肿瘤成分,以及局部治疗引起的炎症如何影响它们。了解如何调节TME是一个探索性的分子领域,它可以引导我们在预防和治疗场景中更好地管理PCa。